Organization
Icahn School of Medicine, Mount Sinai
1 abstract
Abstract
A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).Org: Sarah Cannon Research Institute/Tennessee Oncology, Department of Hematology, University of California San Francisco, Icahn School of Medicine, Mount Sinai, Onc/Hem Care Inc, Center for Discovery and Innovation, Hackensack Meridian Health,